Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint
• By The Pink Sheet
A Merck head-to-head trial showing an efficacy advantage for its osteoporosis agent Fosamax versus Actonel is "misleading" because the claim is based on bone mineral density rather than the preferred fracture risk endpoint, competitors maintain
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights